• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

byKathleen Lau
April 7, 2022
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Bimekizumab is effective for active psoriatic arthritis in biologic-naĂŻve adults

Anti-TNF for inflammatory bowel disease after 24 weeks of pregnancy does not affect neonatal outcomes

Olokizumab is noninferior to adalimumab for the treatment of rheumatoid arthritis

Tags: adalimumabbiologicbiologic persistenceBrodalumabcertolizumabetanerceptIL-12/23 inhibitorIL-17 inhibitorInfliximabIxekizumabpersistencepsoriasispsoriatic arthritisSecukinumabTNF inhibitorustekinumab
Previous Post

Subcortical neurons associated with sleep disturbances in neurodegenerative disease

Next Post

Presence of second midwife during the second active stage of labour reduces the risk of severe perineal trauma

RelatedReports

Long-term use of apremilast for psoriasis associated with an acceptable safety profile
Chronic Disease

Bimekizumab is effective for active psoriatic arthritis in biologic-naĂŻve adults

January 24, 2023
Women electing abortion more likely to be victims of domestic violence
Chronic Disease

Anti-TNF for inflammatory bowel disease after 24 weeks of pregnancy does not affect neonatal outcomes

October 10, 2022
2 Minute Medicine Rewind January 28, 2019
Chronic Disease

Olokizumab is noninferior to adalimumab for the treatment of rheumatoid arthritis

August 26, 2022
Thalidomide may be effective in refractory pediatric Crohn’s disease
Chronic Disease

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

June 21, 2022
Next Post
Women electing abortion more likely to be victims of domestic violence

Presence of second midwife during the second active stage of labour reduces the risk of severe perineal trauma

Quick Take: Effect of Developmentally Adapted Cognitive Processing Therapy for Youth With Symptoms of Posttraumatic Stress Disorder After Childhood Sexual and Physical Abuse

Wellness Check: Mental Health

Psychological impact of COVID-19 on health care workers in Singapore

Dog ownership may reduce loneliness and depression during the COVID-19 pandemic

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options